Issue Date: January 28, 2013
Venture Funding Fell In 2012
The prospect of federal government belt-tightening dampened venture capitalists’ enthusiasm for investing in new biotechnology and cleantech start-ups in 2012, according to the latest MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association. Investments in biotech companies declined 15% compared with 2011 to $4.1 billion, and the number of deals stayed flat. Tighter reimbursements from Medicare, along with lengthy and complicated FDA approval procedures, suppressed investment, says NVCA President Mark G. Heesen. . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society